Antithrombotic therapy in atrial fibrillation: an assessment of compliance with guidelines

Area of Science:

• Cardiology
• Thrombosis Prevention
• Medical Guideline Adherence

Background:

• Atrial fibrillation (AF) poses a significant risk for thromboembolic complications.
• International guidelines exist to prevent these complications, primarily through antithrombotic therapy.
• Physician adherence to these guidelines is crucial for patient outcomes.

Purpose of the Study:

• To evaluate physician compliance with 2001 international guidelines for preventing thromboembolic complications in atrial fibrillation (AF).
• To assess the utilization of warfarin in AF patients at Middlemore Hospital, South Auckland.
• To determine the variance between guideline-recommended and actual antithrombotic treatment.

Main Methods:

• Retrospective review of AF patients presenting to the emergency department (December 2001 - February 2002).
• Comparison of prescribed antithrombotic treatment against ACC/AHA/ESC and ACCP 2001 guidelines.
• Analysis of treatment variance, with a 20% difference considered clinically significant.
• 12-month follow-up for stroke incidence.

Main Results:

• Only 47.5% and 31.2% of patients were managed according to ACC/AHA/ESC and ACCP guidelines, respectively.
• Warfarin utilization was low: 47.4% (ACC/AHA/ESC) and 47.3% (ACCP) of eligible patients received it.
• Older, high-risk patients were less likely to receive guideline-recommended warfarin (p<0.03).
• Four patients experienced strokes; none were on guideline-recommended warfarin.

Conclusions:

• Warfarin is significantly underutilized in atrial fibrillation patients at the institution.
• Current practices deviate substantially from established international guidelines for AF thromboembolic prevention.
• Improved adherence to guidelines, particularly warfarin use, is needed to reduce stroke risk in AF patients.